These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

854 related articles for article (PubMed ID: 30602761)

  • 1. mTOR as a central hub of nutrient signalling and cell growth.
    Kim J; Guan KL
    Nat Cell Biol; 2019 Jan; 21(1):63-71. PubMed ID: 30602761
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Autoregulation of the mechanistic target of rapamycin (mTOR) complex 2 integrity is controlled by an ATP-dependent mechanism.
    Chen CH; Kiyan V; Zhylkibayev AA; Kazyken D; Bulgakova O; Page KE; Bersimbaev RI; Spooner E; Sarbassov DD
    J Biol Chem; 2013 Sep; 288(38):27019-27030. PubMed ID: 23928304
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nutrient signaling to mTOR and cell growth.
    Jewell JL; Guan KL
    Trends Biochem Sci; 2013 May; 38(5):233-42. PubMed ID: 23465396
    [TBL] [Abstract][Full Text] [Related]  

  • 4. mTOR Ser-2481 autophosphorylation monitors mTORC-specific catalytic activity and clarifies rapamycin mechanism of action.
    Soliman GA; Acosta-Jaquez HA; Dunlop EA; Ekim B; Maj NE; Tee AR; Fingar DC
    J Biol Chem; 2010 Mar; 285(11):7866-79. PubMed ID: 20022946
    [TBL] [Abstract][Full Text] [Related]  

  • 5. mTOR-dependent cell survival mechanisms.
    Hung CM; Garcia-Haro L; Sparks CA; Guertin DA
    Cold Spring Harb Perspect Biol; 2012 Dec; 4(12):. PubMed ID: 23124837
    [TBL] [Abstract][Full Text] [Related]  

  • 6. mTORC1- and mTORC2-interacting proteins keep their multifunctional partners focused.
    Bracho-Valdés I; Moreno-Alvarez P; Valencia-Martínez I; Robles-Molina E; Chávez-Vargas L; Vázquez-Prado J
    IUBMB Life; 2011 Oct; 63(10):896-914. PubMed ID: 21905202
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Amino acid signalling upstream of mTOR.
    Jewell JL; Russell RC; Guan KL
    Nat Rev Mol Cell Biol; 2013 Mar; 14(3):133-9. PubMed ID: 23361334
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mammalian target of rapamycin (mTOR) as a potential therapeutic target in various diseases.
    Kaur A; Sharma S
    Inflammopharmacology; 2017 Jun; 25(3):293-312. PubMed ID: 28417246
    [TBL] [Abstract][Full Text] [Related]  

  • 9. mTOR kinase domain phosphorylation promotes mTORC1 signaling, cell growth, and cell cycle progression.
    Ekim B; Magnuson B; Acosta-Jaquez HA; Keller JA; Feener EP; Fingar DC
    Mol Cell Biol; 2011 Jul; 31(14):2787-801. PubMed ID: 21576368
    [TBL] [Abstract][Full Text] [Related]  

  • 10. RhoA modulates signaling through the mechanistic target of rapamycin complex 1 (mTORC1) in mammalian cells.
    Gordon BS; Kazi AA; Coleman CS; Dennis MD; Chau V; Jefferson LS; Kimball SR
    Cell Signal; 2014 Mar; 26(3):461-7. PubMed ID: 24316235
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mammalian target of rapamycin and the kidney. I. The signaling pathway.
    Lieberthal W; Levine JS
    Am J Physiol Renal Physiol; 2012 Jul; 303(1):F1-10. PubMed ID: 22419691
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mechanistic Target of Rapamycin Is a Novel Molecular Mechanism Linking Folate Availability and Cell Function.
    Silva E; Rosario FJ; Powell TL; Jansson T
    J Nutr; 2017 Jul; 147(7):1237-1242. PubMed ID: 28592519
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Disentangling the signaling pathways of mTOR complexes, mTORC1 and mTORC2, as a therapeutic target in glioblastoma.
    Jhanwar-Uniyal M; Dominguez JF; Mohan AL; Tobias ME; Gandhi CD
    Adv Biol Regul; 2022 Jan; 83():100854. PubMed ID: 34996736
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hypoxia Increases IGFBP-1 Phosphorylation Mediated by mTOR Inhibition.
    Damerill I; Biggar KK; Abu Shehab M; Li SS; Jansson T; Gupta MB
    Mol Endocrinol; 2016 Feb; 30(2):201-16. PubMed ID: 26714229
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Growing knowledge of the mTOR signaling network.
    Huang K; Fingar DC
    Semin Cell Dev Biol; 2014 Dec; 36():79-90. PubMed ID: 25242279
    [TBL] [Abstract][Full Text] [Related]  

  • 16. cAMP inhibits mammalian target of rapamycin complex-1 and -2 (mTORC1 and 2) by promoting complex dissociation and inhibiting mTOR kinase activity.
    Xie J; Ponuwei GA; Moore CE; Willars GB; Tee AR; Herbert TP
    Cell Signal; 2011 Dec; 23(12):1927-35. PubMed ID: 21763421
    [TBL] [Abstract][Full Text] [Related]  

  • 17. LKB1 and AMP-activated protein kinase control of mTOR signalling and growth.
    Shaw RJ
    Acta Physiol (Oxf); 2009 May; 196(1):65-80. PubMed ID: 19245654
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The mixed blessing of AMPK signaling in Cancer treatments.
    Sadria M; Seo D; Layton AT
    BMC Cancer; 2022 Jan; 22(1):105. PubMed ID: 35078427
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TORC-specific phosphorylation of mammalian target of rapamycin (mTOR): phospho-Ser2481 is a marker for intact mTOR signaling complex 2.
    Copp J; Manning G; Hunter T
    Cancer Res; 2009 Mar; 69(5):1821-7. PubMed ID: 19244117
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cellular and molecular effects of the mTOR inhibitor everolimus.
    Saran U; Foti M; Dufour JF
    Clin Sci (Lond); 2015 Nov; 129(10):895-914. PubMed ID: 26330617
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 43.